Quantifying protein interactions of pertechnetate: Binding and molecular docking studies

Area of Science:

• Nuclear medicine
• Radiopharmaceutical chemistry
• Biophysical chemistry

Background:

• Pertechnetate (99mTcO4-) is a crucial diagnostic imaging tracer.
• Understanding its interaction with biological molecules is vital for optimizing imaging protocols.
• Limited quantitative data exists on pertechnetate binding to key serum proteins.

Purpose of the Study:

• To quantify the binding of pertechnetate to human serum albumin (HSA), lysozyme (Lz), and insulin (Ins).
• To elucidate the molecular mechanisms underlying pertechnetate-protein interactions.
• To establish clinically relevant reference values for pertechnetate binding.

Main Methods:

• Precipitation-ultracentrifugation assays were employed to quantify binding.
• Molecular docking simulations were utilized to characterize binding sites and affinities.
• Binding fractions and affinities were determined for HSA, Lz, and Ins.

Main Results:

• Weak, saturable binding of pertechnetate was observed, with HSA > Lz > Ins.
• Bound fractions were approximately 22% for HSA, 12% for Lz, and 8-9% for Ins.
• Molecular docking identified shallow, solvent-exposed protein regions with polar/cationic patches as interaction sites.

Conclusions:

• Protein composition, especially albumin, influences pertechnetate availability and clearance.
• Findings provide reference values to optimize tracer timing and enhance scintigraphic image contrast.
• This study offers the first quantitative and mechanistic characterization of pertechnetate binding to relevant proteins.